novo nordisk glp-1 receptor agonist weight management diabetes treatments New loss drugs are about to ship to more American homes How GLP-1 Receptor Agonists Evolved

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment

For an oral drug, the organ that receives the highest dose is the liver 50% of all drugs fail on liver toxicity Pfizer has not been so lucky

Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history

doi: 10.1136/heartjnl-2024-324170

The goal is not just weight lossit is the right treatment for your life